Peter Edman, Head of R&D, will leave Sobi as of December 31, 2011.
"The years in Sobi have been exciting and rewarding", says Peter Edman. "During
this time we have restructured and focused the research operations on
recombinant protein projects within rare diseases, and taken the decision to
advance three development projects into phase III. I have the greatest respect
for the knowledge and competence within Sobi and it was not an easy decision to
leave."
"I want to thank Peter for his contributions to Sobi and we wish him well in his
future endeavors" says Geoffrey McDonough, President and CEO of Sobi. "We remain
committed to delivering our phase III and early stage development pipeline. We
will also utilize our unique competences in protein biochemistry and biologics
manufacturing to acquire new late stage assets in the rare disease area. We will
now start the process to bring in a senior individual with the appropriate
skills to build on this foundation for the future."
For additional information, please contact:
Åsa Stenqvist, Head of Communications and Investor Relations
Tel.: +46 8 697 21 88
About Swedish Orphan Biovitrum (Sobi)
Sobi is a leading European specialty pharmaceutical company focused on providing
and developing pharmaceuticals for patients with rare diseases and significant
medical needs. The portfolio comprises about 60 marketed products, as well as
projects in late clinical phase. Key therapeutic areas are hematological
diseases, autoimmune diseases, hereditary metabolic disorders and therapeutic
oncology. In 2010 Sobi had revenues of SEK 1.9 billion and approximately 500
employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. For more
information please visitwww.sobi.com
The above information has been made public in accordance with the Swedish
Securities Market Act and/or the Financial Instruments Trading Act. The
information was released for public distribution on October 4, 2011 at 8.30 CET.
[HUG#1551789]
